Biocept inc (BIOC)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Net revenues

5,528

3,250

-

-

-

-

-

Net revenues

-

-

5,068

3,223

609

133

134

Costs and expenses:
Cost of revenues

10,977

10,051

9,345

6,920

4,596

2,170

2,329

Gross loss

-

-

-

-

-

-

-2,195

Research and development expenses

4,697

4,468

3,364

2,713

2,857

4,497

3,086

General and administrative expenses

6,970

7,074

7,189

6,560

5,686

5,201

2,513

Sales and marketing expenses

5,940

5,914

6,343

5,054

3,880

2,137

148

Total costs and expenses

28,585

27,509

26,243

21,248

17,020

14,007

-

Loss from operations

-23,056

-24,258

-21,174

-18,025

-16,410

-13,873

-7,944

Other expense:
Interest expense

249

310

482

525

639

1,789

2,070

Warrant inducement expense

1,831

-

-

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

200

-782

Other income

-

-

-

153

102

-

-

Other income

-

-

51

-

-

-

-

Total other expense

-2,081

-310

-431

-372

-537

-1,990

-1,287

Loss before income taxes

-25,138

-24,569

-21,606

-18,397

-16,947

-15,864

-9,232

Income tax expense

-

1

7

2

1

1

0

Net loss and comprehensive loss

-25,138

-24,571

-21,613

-18,399

-16,949

-15,866

-9,233

Deemed dividend related to warrants down round provision

121

636

-

-

-

-

-

Net loss attributable to common shareholders

-25,259

-25,207

-21,613

-

-

-

-

Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:
Basic

20,660

2,798

916

9,578

5,512

3,997

181

Diluted

20,660

2,798

916

9,578

5,512

3,997

181

Net loss per common share:
Basic

-1.22

-9.01

-23.58

-1.92

-3.07

-3.97

-50.80

Diluted

-1.22

-9.01

-23.58

-1.92

-3.07

-3.97

-50.80